SCHEMBL6646359

SCHEMBL6646359

Cc1ccc(C(=O)Nc2ccc3c(c2)CCN3)c(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE7A Q13946 1/20 0.44
▸ PLAU P00749 1/20 0.43
▸ MAPT P10636 3/20 0.41
▸ CFTR P13569 1/20 0.41
▸ ACKR3 P25106 1/20 0.41
▸ EGFR P00533 4/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ DRD2 P14416 1/20 0.40
▸ DRD4 P21917 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ PIR O00625 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6643806 0.84 PDE7A (0.43) PDE7APLAUMAPTCFTRMEN1
SCHEMBL6644513 0.83 PLAU (0.43) PDE7APLAUCFTRMEN1KMT2A
SCHEMBL6646513 0.81 SCN10A (0.57) PDE7APLAUMAPTMEN1KMT2A
SCHEMBL6647449 0.79 PDE7A (0.47) PDE7APLAUMAPTTP53SMN1; SMN2
SCHEMBL6647476 0.79 SCN10A (0.46) PDE7APLAUCFTRMEN1KMT2A
SCHEMBL7131171 0.75 EGFR (0.55) EGFRMEN1KMT2ANPC1RAB9A
SCHEMBL4717835 0.74 NPC1 (0.56) PLAUMAPTMEN1KMT2ANPC1
SCHEMBL6646478 0.73 KCNK3 (0.45) PDE7APLAUMAPTCFTRMEN1
SCHEMBL880654 0.73 NPC1 (0.51) PDE7APLAUMAPTMEN1KMT2A
SCHEMBL31488089 0.73 NPC1 (0.51) PDE7APLAUMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 — — US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR PDE7A 3143/4885PLAU 4416/4885MAPT 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback